In 2018, Translate Bio, Inc. conducted a Phase II trial (NCT03375047) involving adults and seniors aged 18 years or older with cystic fibrosis to investigate the safety and therapeutic efficacy of MRT5005—an aerosol containing codon-optimized CFTR mRNA. The gene discussed is CFTR; the disease is cystic fibrosis.